Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

ClinicalTrials.gov ID: NCT04887857

Public ClinicalTrials.gov record NCT04887857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML)

Study identification

NCT ID
NCT04887857
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Celgene
Industry
Enrollment
6 participants

Conditions and interventions

Interventions

  • CC-486 Drug
  • Venetoclax Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2021
Primary completion
Jan 7, 2024
Completion
Jan 7, 2024
Last update posted
Feb 11, 2024

2021 – 2024

United States locations

U.S. sites
8
U.S. states
7
U.S. cities
7
Facility City State ZIP Site status
Local Institution - 104 Stanford California 94305-5317
Local Institution - 110 Denver Colorado 80218
Local Institution - 105 Boston Massachusetts 02114
Local Institution - 106 New York New York 10029
Local Institution - 113 New York New York 10065
Local Institution - 102 Cleveland Ohio 44195
Local Institution - 111 Oklahoma City Oklahoma 73104
Local Institution - 101 Houston Texas 77003

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04887857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 11, 2024 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04887857 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →